Institution · Frontier Science Foundation-Hellas

Most cited papers from Frontier Science Foundation-Hellas

Frontier Science Foundation-Hellas

What are the most cited papers from Frontier Science Foundation-Hellas?

The most cited paper from Frontier Science Foundation-Hellas is "Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies" (Angela M Wood et al., 2018), with 1,177 citations. Next come "A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)" (817) and "Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial" (789).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 84 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies Angela M Wood et al. · The Lancet Open access246 authors	Apr 2018	1,177
2	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Nathan I. Cherny, Richard Sullivan, Urania G. Dafni et al. · Annals of Oncology Open access	30 May 2015	817
3	Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Mary E.R. O'Brien et al. · The Lancet Oncology	12 Sep 2022	789
4	ESMO-Magnitude of Clinical Benefit Scale version 1.1 Nathan I. Cherny, Urania G. Dafni, Jan Bogaerts et al. · Annals of Oncology Open access	22 Jun 2017	656
5	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Luca Gianni et al. · The Lancet Oncology	26 Feb 2011	614
6	Landmark Analysis at the 25-Year Landmark Point Urania G. Dafni · Circulation Cardiovascular Quality and Outcomes	May 2011	568
7	Association of Adherence to a Healthy Diet with Cognitive Decline in European and American Older Adults: A Meta-Analysis within the CHANCES Consortium Agnes A. M. Berendsen, Jae Hee Kang, Ondine van de Rest et al. · Dementia and Geriatric Cognitive Disorders ReviewOpen access	2017	563
8	Delegatable pseudorandom functions and applications Aggelos Kiayias, Stavros Papadopoulos, Nikos Triandopoulos et al. Conference paper	2013	356
9	Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV‑2 Main Protease Inhibitors Chunlong Ma, Yanmei Hu, Julia Alma Townsend et al. · ACS Pharmacology & Translational Science Open access	9 Oct 2020	276
10	A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Sanjay Popat et al. · Annals of Oncology Open access	22 Sep 2020	273
11	Reconfigurable, Intelligent, and Sustainable Wireless Environments for 6G Smart Connectivity Emilio Calvanese Strinati, George C. Alexandropoulos, Henk Wymeersch et al. · VBN Forskningsportal (Aalborg Universitet) Open access	Oct 2021	262
12	Mediterranean diet and brain structure in a multiethnic elderly cohort Yian Gu, Adam M. Brickman, Yaakov Stern et al. · Neurology Open access	22 Oct 2015	259
13	Spatio‐temporal assessment of illicit drug use at large scale: evidence from 7 years of international wastewater monitoring Iria González‐Mariño et al. · Addiction Open access	23 Oct 2019	243
14	ESMO Guidance for Reporting Oncology real-World evidence (GROW) Luís Castelo-Branco et al. · Annals of Oncology Open access	15 Oct 2023	233
15	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis Urania G. Dafni, Zoi Tsourti, Katerina Vervita et al. · Lung Cancer Review	29 May 2019	229
16	Unraveling the functional dark matter through global metagenomics Georgios A. Pavlopoulos et al. · Nature Open access132 authors	11 Oct 2023	228
17	Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers Charalambos A. Antoniades, Dimitris Tousoulis, Marija Vavlukis et al. · European Heart Journal Open access	19 Jul 2023	225
18	Management of the extraction socket and timing of implant placement: Consensus report and clinical recommendations of group 3 of the XV European Workshop in Periodontology Maurizio S. Tonetti, Ronald E. Jung, Gustavo Ávila‐Ortiz et al. · Journal Of Clinical Periodontology Open access	Jun 2019	220
19	Conceptual Change from the Framework Theory Side of the Fence Stella Vosniadou, Irini Skopeliti · Science & Education	10 Aug 2013	219
20	Skeletal Muscle Adaptations to Interval Training in Patients With Advanced COPD Ioannis Vogiatzis, Gerasimos D. Terzis, Serafeim Nanas et al. · CHEST Journal	Dec 2005	213
21	Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries Urania G. Dafni, Zoi Tsourti, Ioannis Alatsathianos · Breast Care Open access	2019	206
22	Perceived impact of the COVID-19 pandemic on child and adolescent psychiatric services after 1 year (February/March 2021): ESCAP CovCAP survey Alexis Revet et al. · European Child & Adolescent Psychiatry Open access	29 Jul 2021	191
23	Indoor air pollution, physical and comfort parameters related to schoolchildren's health: Data from the European SINPHONIE study Ramen Munir Baloch et al. · The Science of The Total Environment Open access141 authors	6 Jun 2020	184
24	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial Rafael Rosell et al. · The Lancet Respiratory Medicine	10 Apr 2017	184
25	Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study Leo B A van de Putte, R Rau, F C Breedveld et al. · Annals of the Rheumatic Diseases Open access	23 Nov 2003	179
26	Inflammatory and endothelial markers in women with polycystic ovary syndrome Evanthia Diamanti‐Kandarakis, Krystallenia Alexandraki, Christina Piperi et al. · European Journal of Clinical Investigation	12 Sep 2006	171
27	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial Solange Peters et al. · Lung Cancer	3 May 2019	164
28	Risk in Dynamic Arbitrage: The Price Effects of Convergence Trading Péter Kondor · The Journal of Finance	13 Mar 2009	162
29	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP) Rafał Dziadziuszko, Egbert Frederik Smit, Urania G. Dafni et al. · Journal of Thoracic Oncology Open access	27 Feb 2019	161
30	An integrated assessment of climate change impacts for Greece in the near future Christos Giannakopoulos, Effie Kostopoulou, Konstantinos V. Varotsos et al. · Regional Environmental Change Open access	8 Apr 2011	142
31	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) Solange Peters, Enriqueta Felip, Urania G. Dafni et al. · Journal of Thoracic Oncology Open access	12 Nov 2020	141
32	Aggregation‐Based Dynamic Channel Bonding to Maximise the Performance of Wireless Local Area Networks (WLAN) Vivek Parashar, Ramgopal Kashyap, Ali Rizwan et al. · Wireless Communications and Mobile Computing Open access	2022	139
33	Evolution-based approach needed for the conservation and silviculture of peripheral forest tree populations Bruno Fady et al. · Forest Ecology and Management Open access	24 May 2016	133
34	Review of Solar Energetic Particle Prediction Models Kathryn Whitman et al. · Advances in Space Research Open access126 authors	12 Aug 2022	131
35	Consumption of Fish and Long-chain n-3 Polyunsaturated Fatty Acids Is Associated With Reduced Risk of Colorectal Cancer in a Large European Cohort Elom Kouassivi Aglago et al. · Clinical Gastroenterology and Hepatology Open access	25 Jun 2019	127
36	Critical Appraisal of Large Vitamin D Randomized Controlled Trials Stefan Pilz, Christian Trummer, Verena Theiler‐Schwetz et al. · Nutrients Open access	12 Jan 2022	126
37	The MARS feasibility trial: conclusions not supported by data Walter Weder, Rolf Arno Stahel, Paul Baas et al. · The Lancet Oncology	31 Oct 2011	123
38	Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial Solange Peters et al. · Annals of Oncology Open access120 authors	22 Sep 2021	122
39	Effects of rehabilitative exercise on peripheral muscle TNF , IL-6, IGF-I and MyoD expression in patients with COPD Ioannis Vogiatzis, Grigoris K. Stratakos, Davina C M Simoes et al. · Thorax Open access	25 May 2007	122
40	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score Nathan I. Cherny, Elisabeth G.E. de Vries, Urania G. Dafni et al. · Journal of Clinical Oncology Open access	Feb 2019	121
41	A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial Ross Andrew Soo et al. · Annals of Oncology Open access100 authors	25 Nov 2021	119
42	Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas et al. · Cancer Treatment Reviews	13 Dec 2022	118
43	Perovskite nanocrystals for energy conversion and storage Athanasia Kostopoulou, Konstantinos Brintakis, Nektarios K. Nasikas et al. · Nanophotonics Open access	Jun 2018	118
44	A comparative assessment of Greek universities’ efficiency using quantitative analysis Maria Katharaki, George Katharakis · International Journal of Educational Research	2010	116
45	Dysfunctional psychological responses among Intensive Care Unit nurses: a systematic review of the literature Maria N. K. Karanikola, Margarita D. Giannakopoulou, Meropi D. A. Mpouzika et al. · Revista da Escola de Enfermagem da USP ReviewOpen access	Oct 2015	112
46	European soil sampling guidelines for soil pollution studies Sideris Theocharopoulos, Gerhard Wagner, J Sprengart et al. · The Science of The Total Environment	2001	111
47	Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer Evangelos C. Briasoulis, Periklis Pappas, Christian Puozzo et al. · Clinical Cancer Research	6 Oct 2009	106
48	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data Maurice Pérol, Enriqueta Felip, Urania G. Dafni et al. · Annals of Oncology Open access	23 Feb 2022	105
49	Wireless-Optical Network Convergence: Enabling the 5G Architecture to Support Operational and End-User Services Anna Tzanakaki et al. · IEEE Communications Magazine Open access	3 Aug 2017	103
50	Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study Helen J Gogas, Brigitte Dréno, James Larkin et al. · Annals of Oncology Open access	10 Dec 2020	101

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.